Your browser is no longer supported. Please, upgrade your browser.
Settings
ACAD ACADIA Pharmaceuticals Inc. daily Stock Chart
ACAD [NASD]
ACADIA Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-2.53 Insider Own0.10% Shs Outstand122.53M Perf Week2.41%
Market Cap4.59B Forward P/E- EPS next Y-1.91 Insider Trans-39.75% Shs Float122.23M Perf Month15.35%
Income-305.60M PEG- EPS next Q-0.63 Inst Own- Short Float14.17% Perf Quarter35.42%
Sales63.00M P/S72.80 EPS this Y-43.30% Inst Trans0.28% Short Ratio12.47 Perf Half Y4.82%
Book/sh3.40 P/B11.01 EPS next Y25.10% ROA-57.20% Target Price44.89 Perf Year9.13%
Cash/sh3.41 P/C10.99 EPS next 5Y28.90% ROE-62.10% 52W Range20.68 - 40.83 Perf YTD29.79%
Dividend- P/FCF- EPS past 5Y-40.00% ROI-52.90% 52W High-8.33% Beta3.79
Dividend %- Quick Ratio10.70 Sales past 5Y53.00% Gross Margin88.80% 52W Low81.00% ATR1.02
Employees420 Current Ratio10.80 Sales Q/Q31317.50% Oper. Margin- RSI (14)66.30 Volatility2.57% 3.18%
OptionableYes Debt/Eq0.00 EPS Q/Q12.30% Profit Margin- Rel Volume0.58 Prev Close37.67
ShortableYes LT Debt/Eq0.00 EarningsAug 08 AMC Payout- Avg Volume1.39M Price37.43
Recom1.90 SMA203.31% SMA5013.90% SMA20016.98% Volume803,317 Change-0.64%
Nov-11-16Initiated Goldman Neutral
Nov-08-16Upgrade BofA/Merrill Neutral → Buy
Oct-19-16Resumed ROTH Capital Neutral
Oct-04-16Initiated Leerink Partners Mkt Perform $34
Jun-22-16Downgrade BofA/Merrill Buy → Neutral
May-03-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-30-16Reiterated Piper Jaffray Overweight $39 → $44
Feb-08-16Initiated BofA/Merrill Buy $40
Jan-22-16Upgrade Piper Jaffray Neutral → Overweight
Aug-27-15Upgrade Piper Jaffray Neutral → Overweight $48
Aug-07-15Reiterated Needham Buy $38 → $49
Aug-07-15Downgrade Piper Jaffray Overweight → Neutral
Apr-16-15Initiated Leerink Partners Outperform $48
Mar-12-15Reiterated Needham Buy $40 → $38
Feb-24-15Initiated H.C. Wainwright Buy $50
Feb-06-15Resumed ROTH Capital Buy $42
Dec-22-14Reiterated Needham Buy $26 → $40
Aug-07-13Reiterated Needham Buy $16 → $26
Aug-07-13Reiterated Ladenburg Thalmann Buy $15 → $24
Aug-07-13Downgrade MLV & Co Buy → Hold $18 → $20
Sep-26-17 11:13AM  Biotech Acadia Could Rise 30 Percent To $50 Investopedia
Sep-25-17 08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-22-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-21-17 03:00PM  Billionaires Are Gobbling Up This Beaten-Down Biotech Stock: Should You? Motley Fool
Sep-19-17 03:12PM  Supernus Drops SPN-810's Lower Dose Test in Phase III Trials Zacks
09:00AM  ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017 Business Wire
08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-18-17 08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-15-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-14-17 05:50PM  GTx's (GTXI) Enobosarm Positive in Phase II, Shares Down Zacks
11:05AM  Alexion (ALXN) Reports Interim Results for Soliris Study Zacks
Sep-13-17 11:29AM  Perrigo's Stock Up, Starboard's CEO Calls it a Key Pick Zacks
Sep-12-17 11:42AM  Marinus Stock Surges on Successful Phase II Epilepsy Study Zacks
08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Sep-11-17 08:00AM  Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology ACCESSWIRE
Sep-08-17 05:06PM  Nuplazid for Long-Term Care: Revenue Driver for Acadia? Market Realist
03:36PM  Nuplazid Sees Increasing Physician Intent to Prescribe in 2017 Market Realist
02:01PM  Nuplazid Expected to Become a Leading Central Nervous System Drug Market Realist
Sep-07-17 01:24PM  BioMarin Presents Interim Data on BMN 250 from Phase I/II Zacks
11:55AM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : September 7, 2017 Capital Cube
10:32AM  Merck (MRK) Opts for Buying German Immuno-Oncology Biotech Zacks
09:08AM  Acadia Could Report Robust Revenue Growth in 2017 Market Realist
07:37AM  What Analysts Recommend for Acadia Pharmaceuticals in September Market Realist
Sep-05-17 11:47AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017 Capital Cube
Aug-30-17 11:06AM  FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down Zacks
03:00AM  Stocks To Watch: Acadia Pharmaceuticals Sees RS Rating Jump To 83 Investor's Business Daily
Aug-29-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-28-17 07:02PM  Minerva-J&J's Amendment of MIN-202 Contract Wins EU Approval Zacks
Aug-27-17 01:37PM  3 Stocks That Turned $8,000 Into at Least $138,000 in 5 Years Motley Fool
Aug-25-17 10:45AM  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars Zacks
10:23AM  Ultragenyx Files BLA to FDA for Hypophosphatemia Candidate Zacks
Aug-24-17 02:34PM  Kite Pharma at New 52-Week High: What's Driving the Stock? Zacks
Aug-23-17 04:06PM  Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data Zacks
Aug-22-17 08:01AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-21-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-18-17 10:28AM  Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer Zacks
Aug-17-17 10:22AM  FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa Zacks
08:02AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-14-17 02:30PM  Edited Transcript of ACAD earnings conference call or presentation 8-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
10:37AM  Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern Zacks
Aug-12-17 08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-11-17 08:03AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-10-17 08:20AM  Today's Research Reports on Stocks to Watch: Achillion Pharmaceuticals and ACADIA Pharmaceuticals ACCESSWIRE -8.97%
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
Aug-09-17 03:33PM  'Longing' for Acadia Pharmaceuticals? Here's How to Play It TheStreet.com +12.42%
01:43PM  Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today Motley Fool
12:24PM  Acadia Shares Up Big On Strong Sales, Increased Confidence Benzinga
10:25AM  Why Acadia Pharma Is One of Wednesdays Best Earnings Reports 24/7 Wall St.
08:04AM  See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc. Markit
06:00AM  Biotech Acadia Sends a Loud Message to the Market Investopedia
Aug-08-17 11:54PM  Acadia reports 2Q loss Associated Press
04:09PM  Acadia reports 2Q loss Associated Press
04:05PM  ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results Business Wire
01:00PM  Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 10:32AM  Drug Stocks Q2 Earnings Roster for Aug 8: ACAD, JAZZ & More Zacks
Aug-02-17 08:49AM  Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season? Zacks
Aug-01-17 04:07PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : August 1, 2017 Capital Cube
09:00AM  ACADIA Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 8, 2017 Business Wire
Jul-25-17 09:00AM  ACADIA Pharmaceuticals Named to Forbes Magazines List of Worlds Most Innovative Growth Companies Business Wire
Jul-21-17 01:44PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 21, 2017 Capital Cube
01:15PM  7 Potential New Targets for Activist Investor That Made a Killing on Whole Foods TheStreet.com
Jul-18-17 08:16AM  These 2 Companies Have No Competition Motley Fool
Jul-13-17 08:20AM  Today's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V. Accesswire
Jul-12-17 03:07PM  ACADIA Pharmaceuticals, Inc. Value Analysis (NASDAQ:ACAD) : July 12, 2017 Capital Cube
Jul-11-17 09:19AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : July 11, 2017 Capital Cube
Jul-10-17 01:49PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : July 10, 2017 Capital Cube -5.45%
Jun-27-17 02:47PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 27, 2017 Capital Cube
08:54AM  ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACAD-US : June 27, 2017 Capital Cube
Jun-23-17 08:04AM  3 Biotech Stocks for Enterprising Investors Motley Fool
Jun-19-17 02:33PM  3 Value Stocks You Haven't Thought Of Motley Fool
Jun-16-17 03:19PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 16, 2017 Capital Cube
Jun-05-17 01:58PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : June 5, 2017 Capital Cube
Jun-02-17 09:59AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-11-17 09:20PM  Edited Transcript of ACAD earnings conference call or presentation 9-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-10-17 12:25PM  The Acadia Sell-off Is Overdone Investopedia -9.92%
11:39AM  Is This Why Acadia Pharmaceuticals Inc. Is Plunging Today? Motley Fool
May-09-17 06:00PM  Acadia reports 1Q loss Associated Press
04:05PM  ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results Business Wire
01:30PM  Investor Network: ACADIA Pharmaceuticals Inc. to Host Earnings Call Accesswire
May-08-17 09:00AM  ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference on May 16, 2017 Business Wire
May-04-17 12:31PM  What to do when your biotechnology stock gets hit by takeover rumors MarketWatch
May-02-17 09:11AM  What's in the Cards for ACADIA (ACAD) this Earnings Season? Zacks
09:00AM  ACADIA Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 9, 2017 Business Wire
May-01-17 03:31PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : May 1, 2017 Capital Cube
Apr-25-17 07:25AM  Acadia Pharmaceuticals May Just Be the Best Long-Term Play on the Alzheimer's Disease Treatment Market Motley Fool
Apr-24-17 06:00AM  Biotech M&A Plunges as Trump Attacks Drug Companies Investopedia
Apr-19-17 02:07PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 19, 2017 Capital Cube
Apr-05-17 04:14PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : April 5, 2017 Capital Cube
Apr-02-17 02:00PM  What Poker Taught Me About Investing
Mar-31-17 05:03PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
04:10PM  What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track Investor's Business Daily
Mar-30-17 08:00AM  ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer Business Wire
Mar-29-17 09:00AM  ACADIA Pharmaceuticals to Present at Needham & Companys 16th Annual Healthcare Conference on April 5, 2017 Business Wire
Mar-26-17 06:43AM  3 Top Biotech Stocks to Buy in 2017 Motley Fool
Mar-24-17 08:15AM  Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology Accesswire
Mar-06-17 01:25PM  ETFs with exposure to ACADIA Pharmaceuticals, Inc. : March 6, 2017 Capital Cube
Mar-04-17 01:04PM  ACADIA PHARMACEUTICALS INC Financials
Mar-02-17 09:38AM  ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Capital Cube
Feb-28-17 08:29PM  Edited Transcript of ACAD earnings conference call or presentation 28-Feb-17 10:00pm GMT Thomson Reuters StreetEvents
07:23PM  ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. The company has a collaboration with Allergan, Inc. for the development of product candidates related to chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Baity GlennEVP AND GCAug 30Option Exercise1.6216,50726,74194,163Sep 01 05:15 PM
Baity GlennEVP AND GCAug 30Sale34.8726,507924,31567,656Sep 01 05:15 PM
Baity GlennEVP AND GCAug 09Option Exercise1.6214,32223,13791,978Aug 11 05:38 PM
Baity GlennEVP AND GCAug 09Sale34.8814,322499,53477,656Aug 11 05:38 PM
Baity GlennEVP AND GCAug 04Option Exercise1.626,50010,53077,656Aug 08 06:29 PM
Baity GlennEVP AND GCJul 20Option Exercise1.6228,09745,517109,253Jul 21 05:25 PM
Baity GlennEVP AND GCJul 20Sale30.0038,0971,142,91071,156Jul 21 05:25 PM
Baity GlennEVP AND GCJun 22Option Exercise1.621,9033,08383,059Jun 26 05:35 PM
Baity GlennEVP AND GCJun 22Sale30.001,90357,09181,156Jun 26 05:35 PM
Baity GlennEVP AND GCMay 15Option Exercise1.6214,09322,83181,156May 17 05:42 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Option Exercise34.457,856270,6399,527Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 21Sale39.657,856311,4901,671Feb 23 06:01 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Option Exercise28.4466,7521,898,34868,423Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 16Sale39.8866,7522,662,1161,671Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Option Exercise19.611,70033,3373,371Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 15Sale39.651,70067,4051,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Option Exercise6.7126,365176,83993,428Feb 16 07:05 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Option Exercise19.6187,1281,708,58090,759Feb 16 07:06 PM
Moore Terrence OEVP, CHIEF COMMERCIAL OFFICERFeb 14Sale39.6989,0883,535,5731,671Feb 16 07:06 PM
Baity GlennEVP AND GCFeb 14Sale39.6626,3651,045,51767,063Feb 16 07:05 PM
Baity GlennEVP AND GCFeb 01Option Exercise1.5521,07832,67198,141Feb 03 06:50 PM
Baity GlennEVP AND GCFeb 01Sale35.1531,0781,092,38267,063Feb 03 06:50 PM
Baity GlennEVP AND GCDec 28Option Exercise1.625,5008,91077,063Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Option Exercise1.559,80015,19081,363Dec 29 05:09 PM
Baity GlennEVP AND GCDec 27Sale30.469,800298,47471,563Dec 29 05:09 PM
Baity GlennEVP AND GCDec 20Option Exercise1.5510,00015,50081,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 20Sale30.0010,000300,00171,563Dec 21 07:03 PM
Baity GlennEVP AND GCDec 19Option Exercise1.648,63514,16171,563Dec 21 07:03 PM
Baity GlennEVP AND GCNov 10Option Exercise1.5510,20015,81073,121Nov 14 07:00 PM
Baity GlennEVP AND GCNov 10Sale30.0710,200306,68762,921Nov 14 07:00 PM